Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 5,330,000	$ 7,418,000
Operating expenses (income):
Cost of revenues	3,300,000	6,101,000
Research and development	1,387,000	1,509,000
Gain on sale of Verdeca	0	(1,138,000)
Impairment of intangible assets	0	141,000
Change in fair value of contingent consideration	0	(70,000)
Gain on sale of property and equipment	(40,000)	(314,000)
Impairment of property and equipment, net	0	160,000
Impairment of ROU asset	113,000	0
Selling, general and administrative	14,508,000	15,036,000
Total operating expenses	19,268,000	21,425,000
Loss from operations	(13,938,000)	(14,007,000)
Interest income	695,000	289,000
Other income, net	48,000	9,000
Valuation loss on March 2023 PIPE	(6,076,000)	0
Change in fair value of common stock warrant and option liabilities	6,544,000	3,209,000
Issuance and offering costs allocated to liability classified options	(430,000)	(314,000)
Net loss from continuing operations before income taxes	(13,157,000)	(10,814,000)
Income tax expense	(8,000)	(14,000)
Net loss from continuing operations	(13,165,000)	(10,828,000)
Net loss from discontinued operations	(821,000)	(4,784,000)
Net loss	(13,986,000)	(15,612,000)
Net loss attributable to non-controlling interest	(5,000)	(236,000)
Net loss attributable to common stockholders	$ (13,981,000)	$ (15,376,000)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders from continuing operations	$ (10.64)	$ (17.67)
Diluted net loss per share attributable to common stockholders from continuing operations	(10.64)	(17.67)
Basic net loss per share attributable to common stockholders from discontinued operations	(0.66)	(7.98)
Diluted net loss per share attributable to common stockholders from discontinued operations	$ (0.66)	$ (7.98)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	1,236,934	599,389
Weighted average shares - Diluted	1,236,934	599,389
Unrealized gains on available-for-sale securities	$ 101,000	$ 0
Other comprehensive income	101,000	0
Comprehensive loss attributable to common stockholders	(13,880,000)	(15,376,000)
Product
Revenues:
Total revenues	5,313,000	6,422,000
License
Revenues:
Total revenues	17,000	879,000
Royalty
Revenues:
Total revenues	$ 0	$ 117,000